An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Onxeo S.A., a clinical-stage biotechnology company, presented new preclinical data at the ESMO Targeted Anticancer Therapies Congress that supports the combination of AsiDNA™ with PARP inhibitors in homologous recombination repair (HRP) tumor models. Despite PARP inhibitors' limited efficacy in HRP tumors, Onxeo's findings highlight a potential therapeutic strategy to overcome resistance. The data, validated by patient biopsies from the DRIIV-1 clinical trial, suggests that AsiDNA™ can induce functional homologous recombination deficiency and enhance the effectiveness of PARP inhibitors against aggressive tumors.
Positive
New preclinical data confirms the effectiveness of combining AsiDNA™ with PARP inhibitors in HRP tumor models.
The data provides evidence that AsiDNA™ can overcome resistance in HRP tumors, presenting a significant therapeutic opportunity.
Validation in patient biopsies from the DRIIV-1 clinical trial supports AsiDNA™'s potential in clinical settings.
Negative
PARP inhibitors have shown limited efficacy in HRP tumors, presenting a significant unmet need in treatment.
These pioneering data were presented at ESMO Targeted Anticancer Therapies Congress 2022
PARIS--(BUSINESS WIRE)--
Regulatory News:
Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), today announced the presentation of new preclinical data confirming the relevance of combining AsiDNA™ with PARP inhibitors (PARPi) in homologous recombination repair (HRP) tumor models, during poster and oral sessions at the ESMO Targeted Anticancer Therapies Congress (7-8 March, 2022).
Although PARP inhibitors have shown significant benefits in cancer patients with deficient homologous recombination repair (HRD), they show no or very limited efficacy in tumors with active or proficient homologous recombination repair (HRP). The data presented by Onxeo highlight the therapeutic opportunity of combining AsiDNA™ and PARPi in HRP tumors to overcome intrinsic or acquired resistance in clinical situation.
Wael Jdey, Preclinical Lead of Onxeo, stated: “The fact that PARP inhibitors showed limited efficacy in HRP tumors represents a significant unmet need, and addressing these aggressive tumors seems to be challenging. We already showed that AsiDNA disrupts the homologous recombination repair in different HRP tumor models, and therefore, induces a functional HRD that sensitizes HRP tumors to PARP inhibitors. This has been recently validated in preclinical HRP tumor models using more appropriate patient-friendly treatment schedules. Moreover, we also validated the AsiDNA-driven HRD in patient biopsies from DRIIV-1 clinical trial. These new data provide further evidence that our leading drug candidate shows high potential to drive synthetic lethality in combination with PARP inhibitors and reverses the relapse of aggressive tumors during treatment with PARP inhibitors. We are delighted to have had the opportunity to present these new data at the ESMO-TAT Congress and will continue to strengthen our understanding of AsiDNA™’s unique mechanism of action and further explore its capabilities in cancer treatment.”
Full-year 2021 results: Friday, April 1st, 2022 (after market close)
About Onxeo
Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.
platON™ is Onxeo’s proprietary chemistry platform of oligonucleotides acting as decoy agonists, which generates new innovative compounds and broaden the Company’s product pipeline.
AsiDNA™, the first compound from platON™, is a highly differentiated, clinical-stage first-in-call candidate in the field of DNA damage response (DDR) applied to oncology. Its decoy and agonist mechanism acting upstream of multiple DDR pathways results in distinctive antitumor properties, including the ability to prevent or abrogate tumor resistance to targeted therapies such as PARP inhibitors and strong synergy with tumor DNA-damaging agents such as radio-chemotherapy. AsiDNA™ is currently in combination clinical trials in difficult-to-treat solid tumors.
OX401 is a new drug candidate from platON™, optimized to be a next-generation PARP inhibitor acting on both the DNA Damage Response and the activation of immune response, without inducing resistance. OX401 is undergoing preclinical proof-of-concept studies, alone and in combination with immunotherapies.
For further information, please visit www.onxeo.com.
Forward looking statements
This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the risk factors described in the most recent Company’s registration document or in any other periodic financial report and in any other press release, which are available free of charge on the websites of the Company Group (www.onxeo.com) and/or the AMF (www.amf-france.org).
What are the key findings from Onxeo's presentation at the ESMO Congress?
Onxeo presented data showing that combining AsiDNA™ with PARP inhibitors can effectively target HRP tumors, overcoming intrinsic resistance.
What is the significance of the new data on AsiDNA™?
The data indicates that AsiDNA™ can induce a functional homologous recombination deficiency, enhancing the effectiveness of PARP inhibitors in aggressive tumors.
When will Onxeo release its financial results?
Onxeo is scheduled to release its full-year 2021 results on April 1, 2022, after market close.
How does AsiDNA™ work in combination with PARP inhibitors?
AsiDNA™ disrupts homologous recombination repair, effectively sensitizing HRP tumors to the effects of PARP inhibitors.
What are the implications of these findings for cancer treatment?
The findings suggest a new therapeutic strategy for treating HRP tumors, which currently have limited treatment options.
